told cattle feeders this week it will no longer buy animals fed a supplement that's designed ... Zilmax manufacturer Merck Animal Health said in an emailed statement Friday that its product ...

The larger plant will add over 200 full-time jobs as early as 2030. “This investment in our site is designed to increase Merck Animal Health’s ability to meet the growing customer demand for its ...

Plans also call for future expansion at the site, including manufacturing Merck’s cancer-fighting immunotherapy drug Keytruda and other biologic products. Jacobs is engineering contractor for ...

Merck said in its announcement. With the Trump administration threating tariffs on imported products—and specifically targeting pharmaceuticals that are made overseas—this is yet another ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

Early last year, Merck partnered up with Unnatural Products in a $220 million biobucks deal that allows Merck to use Unnatural Products' technology to develop macrocyclic peptide candidates ...

She is also a Certified Stress Management Coach. CNET staff -- not advertisers, partners or business interests -- determine how we review products and services. If you buy through our links ...

a longtime vaccine skeptic, had been a lawyer of record for the plaintiffs in some Gardasil cases against Merck, though he is no longer involved. The case is In re Gardasil Products Liability ...

Merck & Co. on Tuesday opened a new vaccine manufacturing plant in Durham, North Carolina, that will boost the company’s domestic production at a time when President Donald Trump has roiled trade ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.

Along with other products, Merck is banking on the drug’s blockbuster potential to help offset Keytruda’s expected loss of exclusivity toward the end of the decade.

Big picture: We continue to see Merck shares as undervalued, with the market’s fears about Keytruda’s long-term sales trajectory overshadowing potential from newer products and a promising ...